Axicabtagene ciloleucel

Yescarta

2 10^6 CAR-POSITIVE VIABLE T CELLS PER KG OF BODY WEIGHT InjectionUnited StatesMarketedAuthorised 18 Oct 2017

In other countries

The same active substances on other registers, the same brand first.

YescartaBrazil · Gilead Sciences Farmaceutica do Brasil LtdaSame brand
YescartaCanada · 200000000 CELLS / BAG · Suspension · Gilead Sciences Canada INCSame brand
YESCARTA 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSIONSpain · 2 x 10e8 CELULAS · dispersion para perfusion · Kite Pharma Eu B.V.Same brand
YescartaEuropean Union · Kite Pharma EU B.V.Same brand
YescartaCroatiaSame brand
YescartaItaly · Dispersione per infusione · Kite Pharma Eu B.V.Same brand
Yescarta, maximum of 2 x 108 cells/68 ml dispersie voor infusieNetherlands · Oplossing voor infusie · Kite Pharma EU B.V.Same brand

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Axicabtagene ciloleucel

Yescarta

2 10^6 CAR-POSITIVE VIABLE T CELLS PER KG OF BODY WEIGHT InjectionUnited StatesMarketedAuthorised 18 Oct 2017

Ask Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

YescartaSaudi Arabia · Kite Pharma, Inc

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

U.S. Food and Drug Administration

FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.

Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions · Added 11 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Axicabtagene ciloleucel
Strength: 2 10^6 CAR-POSITIVE VIABLE T CELLS PER KG OF BODY WEIGHT
Dosage form: Injection
Route: Intravenous
Register: United States (FDA)
Status: Marketed
Status in the register: Licensed / Rx
Authorised: 18 Oct 2017
Registration: BLA 125643
Marketing authorisation holder: Kite Pharma, Inc.
Procedure: 351(a)
Supply: Rx